# Shalby (NSE: SHALBY) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SHALBY · Pivot · prices to 21 Oct 2026

Shalby (NSE: SHALBY) closed at ₹123.50 on 21 Oct 2026. With a market capitalisation of ₹1,361 Cr, it ranks 1325th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

At its last close the stock traded at 38.9× trailing earnings, against a return on equity of 3.7% in FY26. Over the past year the share price has fallen 49.9%. Its 52-week range is ₹123.36 (21 Oct 2026) to ₹254.95 (21 Oct 2025); the last close is 51.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹287 Cr (+8.5% year on year) and net profit ₹18 Cr, on a consolidated basis. Promoters held 74.33% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹123.50 |
| Market cap | ₹1,361 Cr |
| P/E (trailing) | 38.9 |
| ROE | 3.7% (FY26) |
| ROCE | 7.9% (FY26) |
| Debt to equity | 0.54 |
| 52-week high | ₹254.95 (21 Oct 2025) |
| 52-week low | ₹123.36 (21 Oct 2026) |
| 1-year return | −49.9% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹287 Cr | +8.5% | ₹18 Cr | — | ₹1.72 |
| Q3 FY26 | ₹272 Cr | −1.3% | ₹1 Cr | — | ₹0.12 |
| Q2 FY26 | ₹285 Cr | +6.7% | ₹7 Cr | +208.5% | ₹0.68 |
| Q1 FY26 | ₹296 Cr | +6.3% | ₹8 Cr | −47.9% | ₹0.71 |
| Q4 FY25 | ₹265 Cr | +8.5% | −₹12 Cr | −176.0% | −₹1.13 |
| Q3 FY25 | ₹276 Cr | +27.6% | −₹3 Cr | −115.7% | −₹0.28 |
| Q2 FY25 | ₹268 Cr | +12.4% | ₹2 Cr | −91.4% | ₹0.22 |
| Q1 FY25 | ₹279 Cr | +18.4% | ₹15 Cr | −29.2% | ₹1.37 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,087 Cr | ₹2 Cr |
| FY24 | ₹934 Cr | ₹84 Cr |
| FY23 | ₹805 Cr | ₹68 Cr |
| FY22 | ₹699 Cr | ₹54 Cr |
| FY21 | ₹431 Cr | ₹42 Cr |
| FY20 | ₹487 Cr | ₹28 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 74.33%
- Foreign institutions: 4.46%
- Domestic institutions: 0.30%
- Non-institutions: 20.26%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Amrutanjan Health Care](https://app.pivotnow.in/stock/AMRUTANJAN) | ₹501.00 | ₹1,448 Cr | 25 | — |
| [Jagsonpal Ser](https://app.pivotnow.in/stock/JAGSNPHARM) | ₹217.95 | ₹1,435 Cr | 34.5 | — |
| [Anlon Healthcare](https://app.pivotnow.in/stock/AHCL) | ₹26.92 | ₹1,431 Cr | 44.1 | — |
| [TTK Healthcare](https://app.pivotnow.in/stock/TTKHLTCARE) | ₹1,007.60 | ₹1,424 Cr | 21.7 | — |
| [Kopran](https://app.pivotnow.in/stock/KOPRAN) | ₹279.00 | ₹1,347 Cr | 52.3 | — |
| [Fermenta Biotech](https://app.pivotnow.in/stock/FERMENTA) | ₹456.75 | ₹1,344 Cr | — | — |

## Questions and answers

### What is the share price of Shalby today?

Shalby (NSE: SHALBY) last closed at ₹123.50 on 21 Oct 2026. Its 52-week high is ₹254.95 and its 52-week low is ₹123.36.

### What is the market cap of Shalby?

Shalby's market capitalisation is ₹1,361 Cr (₹1,361 Cr) at the 19 Oct 2026 close, ranking 1325th among the NSE companies Pivot tracks.

### What is the P/E ratio of Shalby?

Shalby trades at a trailing P/E of 38.9. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 34.5.

### What is the ROE and ROCE of Shalby?

Return on equity was 3.7% in FY26 and return on capital employed was 7.9% in FY26 (consolidated figures).

### Is Shalby a debt-free company?

No. Shalby's debt-to-equity ratio was 0.54 in FY26, with total debt of ₹153 Cr.

### What were Shalby's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Shalby reported revenue of ₹287 Cr, +8.5% year on year, and net profit of ₹18 Cr.

### How has Shalby stock performed over the last year?

Shalby's share price has fallen 49.9% over the past year, −24.1% over three months and −8.6% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Shalby?

As of 30 Jun 2026: promoters 74.33%, foreign institutions 4.46%, domestic institutions 0.30%, non-institutions 20.26%.

### Who are Shalby's competitors?

The listed Pharma & Healthcare companies closest to Shalby by market cap are Amrutanjan Health Care, Jagsonpal Ser, Anlon Healthcare, TTK Healthcare, Kopran and Fermenta Biotech.

### Is Shalby a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Shalby's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SHALBY against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.